Australian Manufacturing Forum member viewpoint by Kris Gale
Rock and roll fans might recognise the source material of the headline quote.
It is The Who’s “Won’t Get Fooled Again” – Roger Daltrey giving voice to the entrenched frustration Pete Townshend utilised to drive that band to greater and greater heights.
And so it is with the Bill currently before the Federal Parliament, which introduces a series of reforms to the R&D Tax Incentive (the Incentive).
Close inspection reveals that the Bill is virtually unchanged from the first version that was unanimously rejected by the Senate Economics Legislation Committee (SELC) in February 2019.
The new Bill has been immediately referred to the SELC with a report back date of 30 April and submissions can be lodged on or before 6 March: HERE
In summary, my company MJA believes that the unanimous rejection of the first Bill by the SELC comprising Government, Opposition and Cross-Bench Senators should be repeated with respect to the review of the second Bill.
It is legislating a major reduction in R&D support at a time when the Australian innovation economy can least afford it.
Since 2015, the Incentive has had rate cuts, annual claim limits and controversial administrative practices imposed upon it.
The net result is that the cost to revenue of the Incentive has fallen significantly as program participation has tailed off and R&D activity has been repressed.
The program’s KPI, business expenditure on R&D (BERD) as a percentage of GDP, has slumped below one per cent.
This is further evidenced by the recent slew of reports documenting Australia slipping down the international innovation measurement ladders.
One would think that the Government would be seeking to bolster the effectiveness of the Incentive in the current environment rather than subjecting it to further cuts and restrictions. But this is incontrovertibly not the case.
Let’s detail the issues with the Bill that prompted its unanimous rejection by the SELC:
# an illogical and unworkable intensity test that slashes support for companies turning over $20 million or more annually;
# a further paring back of assistance for smaller organisations;
# yet more “enforcement” resources;
# and an unprecedented compulsion to publish a company’s claim amount in exchange for the right to access the Incentive.
All these features have been retained in the Bill despite the concerns clearly detailed in the SELC Report.
In fact, our comparison of the Bill reveals the following differences only:
# The intensity rate changes for the Non-Refundable R&D Tax Offset (see discussion below)
The start date of the Bill has been pushed back from 1 July 2018 to 1 July 2019 which means that, if enacted, it will have retrospective effect
# Changes to Part IVA (s 177) to individually identify the Refundable R&D Tax Offset and the Non-Refundable R&D Tax Offset. This means that, of all the offsets, only the foreign income tax offset, the innovation tax offset (early stage venture capital limited partnerships and ESIC), the exploration credit and now R&D are specifically identified. There is no explanation of why this is needed and how this will separate behaviour changes inspired by the program and its compliance methods to get the tax benefit as opposed to inappropriate schemes to get the tax benefit.
# Minor and irrelevant corrections to the note in s 40-293, the titles in Subdivision 355-H on balancing adjustments and a renumbering of the claim publication provision from 3G to 3H in the Tax Administration Act 1953
The two Bills are virtually identical and most attention has focused on the reworking of the rates of tax offset associated with the proposed intensity requirements for Non-Refundable R&D Tax Offset companies.
First of all, in order to meet the current available level of support under the universal offset rate of 38.5%, a company group would need to have an R&D intensity level of 13 per cent. This was 13.25 per cent under the first Bill.
Most organisations will get nowhere this result and will be worse off – so no improvement here.
Secondly, commentators accept that the vast majority of claimants will fall within the new Bill’s bottom intensity tier of 0 per cent – four per cent and only be eligible for an anaemic offset rate of 34.5 per cent.
This is half a percentage point up from the first Bill but the intensity parameter has jumped from two per cent to four.
Neither the Triple F Report or Innovation and Science Australia were prepared to posit an intensity rate greater than two per cent. Treasury clearly has no such qualms.
This reduction will decimate participation rates in the Incentive.
In the program’s 35 year history, the lowest level of permanent difference is 7.5 per cent. This Bill drops the level to 4.5%, an historic low.
When you factor in compliance costs (generally regarded as two per cent and growing), the impact of the second Bill is to reduce the net support from a net 6.5 per cent to 2.5% per cent.
This represents a slashing of support by more than 60% per cent. This is not sustainable and will drive the Incentive to the point of irrelevance for the incredibly diverse range of organisations doing R&D with a turnover above the modest level of $20 million.
It is imperative that interested parties make their concerns known by making a submission to the SELC by Friday, 6 March: and by offering to appear in front of the Committee.
Kris Gale is chairman of Michael Johnson Associates, a company focused on the direct delivery of R&D tax benefits to Australian companies from start ups to the very largest. He can be contacted on 02 9810 7211 or email [email protected]
Picture: Kris Gale
Subscribe to our free @AuManufacturing newsletter here.